^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    azacitidine

    i
    Other names: U-18496, Aza-C, NS 17, NS-17, Aza C, NSC-102816
    Company:
    Generic mfg.
    Drug class:
    DNMT inhibitor
    Related drugs:
    1d
    Single-Center Phase 1 Study With Escalating Doses of Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia (AML). TOCIVENA (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Nantes University Hospital
    New P1 trial
    |
    Venclexta (venetoclax) • azacitidine • Actemra IV (tocilizumab)
    1d
    A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=45, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132
    |
    Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
    2d
    A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2/3, N=40, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P2/3 trial
    |
    azacitidine
    2d
    CA209-9WW: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2025 --> Apr 2026
    Trial completion date
    |
    Opdivo (nivolumab) • azacitidine
    3d
    Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    azacitidine
    3d
    A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS (clinicaltrials.gov)
    P1, N=100, Recruiting, Apollo Therapeutics Ltd | Phase classification: P1/2 --> P1
    Phase classification
    |
    Venclexta (venetoclax) • azacitidine
    3d
    GANCE: Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML (clinicaltrials.gov)
    P2, N=25, Recruiting, First Affiliated Hospital of Zhejiang University | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Dec 2028
    Enrollment open • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2)
    |
    FLT3-ITD mutation
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine
    4d
    MDS: Pacritinib With Aza for Upfront Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=25, Not yet recruiting, Thomas Jefferson University
    New P1/2 trial
    |
    azacitidine • Vonjo (pacritinib)
    6d
    Pyrimethamine overcomes resistance to hypomethylating agents by reducing de-novo pyrimidine synthesis. (PubMed, Exp Hematol)
    The DNA hypomethylating agents (HMAs) 5-azacitidine and decitabine are the backbone of disease modifying therapy in myelodysplastic syndromes (MDS). We show that pyrimethamine, an FDA-approved antifolate, induces apoptosis across leukemic models, synergizes with venetoclax, and restores sensitivity in HMA- and venetoclax-resistant leukemia. Pyrimethamine promotes differentiation of stem and progenitor cells in primary MDS samples and in combination with venetoclax directly inhibits pyrimidine synthesis, revealing a clinically actionable strategy to overcome a key mechanism of therapeutic resistance.
    Journal
    |
    DNMT1 (DNA methyltransferase 1)
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    8d
    A prospective, single-arm, multicenter clinical study of a maintenance regimen comprising Venetoclax combined with Azacitidine for adult patients with newly diagnosed acute myeloid leukemia (non-APL) who have achieved remission following standard induction and consolidation chemotherapy (ChiCTR2500114099)
    P=N/A, N=80, Not yet recruiting, Mianyang Central Hospital; Mianyang Central Hospital
    New trial
    |
    Venclexta (venetoclax) • azacitidine
    8d
    Gilteritinib plus venetoclax and azacitidine in FLT3-mutated acute myeloid leukemia: a multicenter retrospective cohort study (ChiCTR2500112896)
    P=N/A, N=111, Completed, The first affiliated hospital, Zhejiang University School of Medicine; The first affiliated hospital, Zhejiang University School of Medicine
    New trial
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine
    8d
    Clinical Study on Efficacy and Safety of G-CSF Combined with Azacitidine and Venetoclax in the Treatment of Adult Acute Myeloid Leukemia (ChiCTR2500112100)
    P=N/A, N=34, Not yet recruiting, The Second Affiliated Hospital of Guangxi Medical University; The Second Affiliated Hospital of Guangxi Medical University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • lisaftoclax (APG-2575)